Richard Pazdur, MD | Authors

Articles

Requirements for a Breakthrough Therapy Designation

October 04, 2013

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.